Paul Tudor Jones Zentalis Pharmaceuticals, Inc. Call Options Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$51.2 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$31.4 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$20.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$17.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$16.5 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $209M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...